辛伐他汀在慢性阻塞性肺疾病大鼠模型中的早期干预作用

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (710 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨早期给予辛伐他汀干预对慢性阻塞性肺疾病（COPD）大鼠模型的影响及机制。方法将42只大鼠（Wistar，清洁级）随机分为空白组、模型组和他汀组，每组14只。采用烟熏加气道内滴入脂多糖法复制COPD大鼠模型，他汀组在造模2周后加用辛伐他汀（5 mg/kg）灌胃治疗。观察大鼠一般表现；监测体重变化；采用生物素双抗体夹心酶联免疫吸附法测定血清及支气管肺泡灌洗液（BALF）中白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）水平；血球计数仪计数BALF中白细胞计数；免疫组织化学染色法测定肺组织中基质金属蛋白酶（MMP-9）的表达；图像分析系统分析各组大鼠病理改变。结果模型组及他汀组大鼠体重较空白组减轻（P ＜ 0.01）。血清和BALF中IL-6、TNF-α水平，模型组及他汀组较空白组增加（P ＜ 0.05），他汀组较模型组降低（P ＜ 0.05）。肺组织中MMP-9表达，模型组较空白组增高（P ＜ 0.01），他汀组较模型组降低（P ＜ 0.05）。模型组及他汀组大鼠肺组织符合COPD病理学改变，他汀组组织损伤、重塑及炎症浸润程度较模型组降低。结论香烟吸入联合呼吸系统感染可加重肺部及全身炎性反应程度，增加蛋白酶过度表达，参与COPD的发生发展。早期给予辛伐他汀治疗，可在一定程度上减轻肺组织损伤及重塑，降低炎性反应程度，缓解蛋白酶系统亢进。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杨凯1 郭璐2▲ 刘跃建2 胡蓉1 段文娟3

关键词 ：他汀, 慢性阻塞性肺疾病, 大鼠, 基质金属蛋白酶9

Abstract：Objective To explore the effects of early stage administration of Simvastatin on chronic obstructive pulmonary disease (COPD) rat model and its mechanism. Methods 42 SPF Wistar rats were randomly divided into three groups (n=14): blank group, model group and Simvastatin group. COPD rat models were replicated with the method of inhaling cigarette smoke and intratracheal instillation of LPS. Simvastatin group rats were gave lavage treatment with Simvastatin (5 mg/kg) after 2 weeks when COPD model was established. Usual manifestations and body weights of rats from the three groups were monitored. The levels of IL-6 and TNF-α in serum and BALF were measured by double antibody sandwich enzyme-linked immuno sorbent assay (ELISA). Leukocyte in BALF was counted by haemocytometer. The expression of MMP-9 in the lung tissues was measured by immunohistochemically. Pathological examination of lung tissues from every group was analyzed by image analysis system. Results Body weights of rats from the model group and Simvastatin group were significantly reduced compared with those of the blank group (P ＜ 0.01). Levels of IL-6 and TNF-α in serum and BLAF were higher in the model group and Simvastatin group than the blank group (P ＜ 0.05). Compared with model group, the levels in Simvastatin group were decreased (P ＜ 0.05). The expression of MMP-9 in lung tissues, model group was increased than the blank group (P ＜ 0.05), Simvastatin group was lower than the model group (P ＜ 0.05). The pathologic characteristics of COPD was observed in the lung tissues from Simvastatin group and model group. Copmared with the model group, lung tissue injury, remodeling and inflammatory infiltration in Simvastation group was attenuated. Conclusion Cigarettes inhalation combined with respiratory infections can aggravate pulmonary and systemic inflammation, and up-regulate the expression of proteases, all of which are involved in the genesis and development of COPD. Simvastatin therapy as an early intervention can alleviate the lung tissue injury and remodeling to a certain degree, attenuate pulmonary and systemic inflammation and alleviate the over-activation of proteasesystem.

Key words： Statin COPD Rat MMP-9

基金资助:四川省科技计划项目（2013JY0177）。

通讯作者: ▲通讯作者

作者简介: 杨凯（1986.7-），硕士研究生；研究方向：COPD治疗与康复，肺血管疾病发病与治疗。

引用本文:

杨凯1 郭璐2▲ 刘跃建2 胡蓉1 段文娟3. 辛伐他汀在慢性阻塞性肺疾病大鼠模型中的早期干预作用[J]. 中国医药导报, 2017, 14(34): 8-12.
YANG Kai1 GUO Lu2▲ LIU Yuejian2 HU Rong1 DUAN Wenjuan3. Effect of early intervention of Simvastatin on chronic obstructive pulmonary disease rats model. 中国医药导报, 2017, 14(34): 8-12.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I34/8

[1] 陈亚红.2017年GOLD慢性阻塞性肺疾病诊断、治疗及预防的全球策略解读[J].中国医学前沿杂志，2017，9（1）：37-46.
[2] Young RP，Hopkins R，Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease：a review of the evidence [J]. Postgrad Med J，2009，85（1006）：414-421.
[3] Dobler CC，Wong KK，Marks GB. Associations between statins and COPD：a systematic review [J]. BMC Pulm Med，2009，9：32.
[4] Agusti A，Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease [J]. Proc Am Thorac Soc，2012，9（2）：43-46.
[5] Garcia-Rio F，Miravitlles M，Soriano JB，et al. Systemic inflammation in chronic obstructive pulmonary disease：a population-based study [J]. Respir Res，2010，11：63.
[6] 潘兆宝，范玉梅，韩守华，等.血清IL-6、IL-8、纤维蛋白原水平在COPD患者中的变化及其与预后的关系[J].国际检验医学杂志，2017，38（9）：1261-1263.
[7] Yeganeh B，Wiechec E，Ande S R，et al. Targeting the mevalonate cascade as a new therapeutic approach in heart disease，cancer and pulmonary disease [J]. Pharmacol Ther，2014，143（1）：87-110.
[8] Ghittoni R，Napolitani G，Benati D，et al. Simvastatin inhibits the MHC class Ⅱ pathway of antigen presentation by impairing Ras superfamily GTPases [J]. Eur J Immunol，2006， 36（11）：2885-2893.
[9] 吴轶赟，廖浪霞.辛伐他汀治疗慢性阻塞性肺疾病的疗效及其对患者C反应蛋白、前白蛋白和肺功能的影响[J].海南医学，2016，27（23）：3807-3810.
[10] Pourfarzam S，Yaraee R，Hassan ZM，et al. Chemokines，MMP-9 and PMN elastase in spontaneous sputum of sulfur mustard exposed civilians：Sardasht-Iran Cohort Study [J]. Int Immunopharmacol，2013，17（3）：958-963.
[11] Simpson JL，McDonald VM，Baines KJ，et al. Influence of age，past smoking，and disease severity on TLR2，neutrophilic inflammation，and MMP-9 levels in COPD [J]. Mediators Inflamm，2013，2013：462934.
[12] 张立海，李新玲，王丽红，等.辛伐他汀对慢阻肺大鼠MMP-9及其抑制剂表达的影响[J].临床肺科杂志，2016， 21（6）：1018-1020.
[13] Kamio K，Liu X D，Sugiura H，et al. Statins inhibit matrix metalloproteinase release from human lung fibroblasts [J]. Eur Respir J，2010，35（3）：637-646.
[14] Kim SE，Thuy TTT，Lee JH，et al. Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract [J]. Exp Mol Med，2009，41（4）：277-287.
[15] Young RP，Hopkins R，Eaton TE. Pharmacological actions of statins：potential utility in COPD [J]. Eur Respir Rev，2009，18（114）：222-232.
[16] Alexeeff SE，Litonjua AA，Sparrow D，et al. Statin use reduces decline in lung function：VA Normative Aging Study [J]. Am J Respir Crit Care Med，2007，176（8）：742-747.
[17] Kaczmarek P，Sladek K，Skucha W，et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease [J]. Pol Arch Med Wewn，2010，120（1-2）：11-18.
[18] Horita N，Miyazawa N，Kojima R，et al. Statins reduce all-cause mortality in chronic obstructive pulmonary disease：A systematic review and meta-analysis of observational studies [J]. Respiratory Research，2014，15（1）：80.
[19] Criner GJ，Connett JE，Aaron SD，et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD [J]. N Engl J Med，2014，370（23）：2201-2210.
[20] 董微，康萍，钟祥柱，等.他汀类药物在慢性阻塞性肺疾病稳定期患者中的作用[J].实用医学杂志，2015，31（11）：1835-1837.